FHIT: From gene discovery to cancer treatment and prevention

Lancet Oncology

Volumn 3, Issue 12, 2002, Pages 748-754

  Pekarsky, Yuri ^a   Zanesi, Nicola ^a   Palamarchuk, Alexey ^a   Huebner, Kay ^a   Crose, Carlo M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FRAGILE HISTIDINE TRIAD PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER PREVENTION; CANCER THERAPY; CHROMOSOME 3P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME INACTIVATION; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; FAMILIAL CANCER; GENE IDENTIFICATION; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CANCER; LUNG CANCER; MOLECULAR GENETICS; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 0036900616     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00931-2     Document Type: Review

References (66)

1. Croce CM. Role of chromosome translocations in human neoplasia. Cell 1987; 49: 155-56.
2. Soloman E, Borrow J, Goddart A. Chromosome aberrations and cancer. Science 1991; 254: 1153-60.
3. Ar-Rushdi A, Nichikura K, Erikson J, et al. Differential expression of the translocated and of the untranslocated c-MYC oncogene in Burkitt’s lymphoma. Science 1983; 222: 390-93.
4. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the BCL-2 gene in human follicular lymphoma. Science 1985; 228: 1440-43.
5. Arakawa H, Nakamura T, Zhadanov AB, et al. Identification and characterization of the ARP1 gene, a target for the human acute leukemia ALL1 gene. Proc Natl Acad Sci USA 1998; 95: 4573-78.
6. Weinberg R. Tumor suppressor genes. Science 1991; 254: 1138-46.
7. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-47.
8. Wigler MH, Parson RA, Druck T, et al. Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Cancer Res 1995; 55: 5348-53.
9. Kastury K, Baffa R, Druck T, et al. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996; 56: 978-83.
10. Naylor SL, Johnson BE, Minna JD, et al. Loss of heterozygosity of chromosome 3p markers in small cell lung cancer. Nature 1987; 329: 451-54.
11. Hibi K, Takahashi T, Yamakawa K, et al. Three distinct regions involved in 3p deletions in human lung cancer. Oncogene 1992; 7: 445-49.
12. Huebner K, Hadaczek P, Siprashvili Z, et al. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochem Biophys Acta (Reviews on Cancer) 1997; 1332: M65-M70.
13. Glover TW, Stein CK. Chromosome breakage and recombination at fragile sites. Am J Hum Genet 1988; 43: 265-73.
14. Glover TW, Coyle-Morris JF, Frederick PL, et al. Translocation t(3;8) (p14.2;q24.1) in renal cell carcinoma affects expression of the common fragile site at 3p14 (FRA3B) in lympocytes. Cancer Genet Cytogenet 1988; 31: 69-73.
15. Rassool FV, McKeithan TW, Neilly ME, et al. Preferential integration of marker DNA into the chromosomal fragile site at 3p14.2: a novel approach to cloning fragile sites. Proc Natl Acad Sci USA 1991; 88: 6657-61.
16. Ohta M, Inoue H, Cotticelli MG, et al. The human FHIT gene, spanning the chromosome 3p14.2 fragile site and renal cell carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-97.
17. Inoue H, Ishii H, Alder H, et al. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci USA 1997; 94: 14584-89.
18. Mimori K, Druck T, Inoue H, et al. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc Natl Acad USA 1999; 96: 7456-61.
19. Druck T, Hadaczek P, Fu T-B, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997; 57: 504-12.
20. Baffa R, Veronese M L, Santoro R, et al. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998; 58: 4708-14.
21. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996; 85: 17-26.
22. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032-37.
23. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997; 89: 857-62.
24. Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of FHIT expression in non-small-cell lung cancer. Br J Cancer 2000; 82: 1191-97.
25. Hadaczek P, Siprashvili Z, Markiewski M, et al. Absence or reduction FHIT expression in most clear cell renal carcinomas. Cancer Res 1998; 58: 2946-51.
26. Greenspan DL, Connoly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997; 57: 4692-98.
27. Simon B, Bartsch D, Barth P, et al. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res 1998; 58: 1583-87.
28. Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56: 3173-79.
29. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, et al. Reduced FHIT expression in sporadic and BRCA-2-linked breast carcinomas. Cancer Res 1999; 59: 2682-89.
30. Campiglio M, Pekarsky Y, Menard S, et al. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999; 59: 3866-69.
31. Gatalica Z, Lele SM, Rampy BA, Norris BA. The expression of FHIT protein is related inversely to disease progression in patients with breast carcinoma. Cancer 2000; 88: 1378-83.
32. Zochbauer-Muller S, Fong KM, Maitra A, et al. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001; 61: 3581-85.
33. Morikawa H, Nakagawa Y, Hashimoto K, et al. Frequent altered expression of fragile histidine triad protein in human colorectal adenomas. Biochem Biophys Res Commun 2000; 278: 205-10.
34. Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000; 60: 18-21.
35. Birrer MJ, Hendricks D, Farley J, et al. Abnormal FHIT expression in malignant and premalignant lesions of the cervix. Cancer Res 1999; 59: 5270-74.
36. Connoly DC, Greenspan DL, Wu R, et al. Loss of FHIT expression in invasive cervical carcinomas and intraepithelial associated with invasive disease. Clin Cancer Res 2000; 60: 3505-10.
37. Mori M, Mimori K, Shiraishi T, et al. Altered expression of FHIT in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 2000; 60: 1177-82.
38. Pylkkanen L, Wolff H, Stjernavall T, et al. Reduced FHIT protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int J Oncol 2002; 20: 285-90.
39. Chizhikov V, Chikina S, Gasparian A, et al. Molecular follow-up of preneoplastic lesions in bronchial epithelium of former Chernobyl clean-up workers. Oncogene 2002; 21: 2398-405.
40. Mori M, Mimori K, Masuda T, et al. Absence of MSH2 protein expression is associated with alteration of the FHIT locus and FHIT protein expression in colorectal carcinoma. Cancer Res 2001; 61: 7379-82.
41. Turner BC, Ottey M, Zimonjik DB, et al. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res 2002; 62: 4054-60.
42. Le Beau MM, Rassool FV, Neilly ME, et al. Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet 1998; 7: 755-61.
43. Hellman A, Rahat A, Scherer SW, et al. Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol Cell Biol 2000; 20: 4420-27.
44. Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of FHIT in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771-76.
45. Ji L, Fang B, Yen N, et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59: 3333-39.
46. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96: 8489-92.
47. Roz L, Gramegna M, Ishii H, et al. Restoration of fragile histidine thriad (FHIT) expression induces apotosis and suppreses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002; 99: 3615-20.
48. Werner NS, Siprashvili Z, Fong LY, et al. Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous FHIT expression. Cancer Res. 2000; 60: 2780-85.
49. Ishii H, Dumon KR, Vecchione A, et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001; 61: 1578-84.
50. Dumon KR, Ishii H, Vecchione A, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001; 61: 4827-36.
51. Pekarsky Y, Drick T, Cotticelli MG, et al. The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells. Cancer Res 1998; 58: 3401-08.
52. Shiraishi T, Druck T, Mimori K, et al. Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit. Proc Natl Acad Sci USA 2001; 98: 5722-27.
53. Fong LY, Fidanza V, Zanesi N, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 2000; 97: 4742-47.
54. Zanesi N, Fidanza V, Fong LY, et al. The tumor spectrum in Fhit-deficient mice. Proc Natl Acad Sci USA 2001; 98: 10250-55.
55. Yang CS. Research on esophageal cancer in China. Cancer Res 1980; 40: 2633-44.
56. Tollefson L. The use of epidemiology, scientific data, and regulatory authority to determine risk factors in cancer of some organs of the digestive system. Regul Toxicol Pharmacol 1985; 5: 255-75.
57. Lu SH, Montesano R, Zhang MS, et al. Relevance of N-nitrosmines to esophageal cancer in China. J Cell Physiol Suppl 1986; 4: 51-58.
58. Ishii H, Dumon KR, Vecchione A, et al. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA 2001; 286-2441-49.
59. Dumon KR, Ishii H, Fong LY, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 2001; 98: 3346-51.
60. Brenner C, Bieganowski P, Pace HC, Huebner K. The histidine triad superfamily of nucleotide-binding proteins. J Cell Physiol 1999; 181: 179-87.
61. 3 triphosphate hydrolase. Biochemistry 1999; 35: 11529-35.
62. Pace HC, Garrison PN, Robinson AK, et al. Genetic, biochemical and crystallographic characterization of FHIT-substrate complexes as the active signaling form of FHIT. Proc Natl Acad Sci USA 1998; 95: 5484-89.
63. Pekarsky Y, Campiglio M, Siprashvili Z, et al. Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc Natl Acad of Sci USA 1998; 95: 8744-49.
64. Davidson JN, Peterson M. Origin of genes encoding multi-enzymatic proteins in eukaruyotes. Trends Genet 1997; 13: 281-85.
65. Chaudhuri AR, Khan IA, Prasad V, et al. The tumor supressor protein FHIT: a novel interaction with tubulin. J Biol Chem 1999; 274: 24378-82.
66. Schilichting I, Almo SC, Rapp G, et al. Time-resolved X-ray crystallographic study of the conformational change in Ha-RAS p21 protein on GTP hydrolysis. Nature 1990; 345: 309-15.